Quinethazone

DB01325

small molecule approved

Deskripsi

Quinethazone, marketed as Hydromox, is a thiazide diuretic indicated for hypertension. Patients may experience adverse reactions such as dizziness, dry mouth, nausea, and hypokalemia.

Struktur Molekul 2D

Berat 289.739
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

1 Data
  • 1. Take with food. Food increases bioavailability.

Interaksi Obat

1100 Data
Nicotine The risk or severity of adverse effects can be increased when Quinethazone is combined with Nicotine.
Mecamylamine The risk or severity of adverse effects can be increased when Quinethazone is combined with Mecamylamine.
Pentolinium The risk or severity of adverse effects can be increased when Quinethazone is combined with Pentolinium.
Trimethaphan The risk or severity of adverse effects can be increased when Quinethazone is combined with Trimethaphan.
Hexamethonium The risk or severity of adverse effects can be increased when Quinethazone is combined with Hexamethonium.
Cyclopentamine The risk or severity of adverse effects can be increased when Quinethazone is combined with Cyclopentamine.
Allopurinol The risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Quinethazone.
Carbamazepine The risk or severity of adverse effects can be increased when Quinethazone is combined with Carbamazepine.
Cyclophosphamide The risk or severity of granulocytopenia can be increased when Quinethazone is combined with Cyclophosphamide.
Diazoxide The risk or severity of hypotension, hyperglycemia, and hyperuricemia can be increased when Quinethazone is combined with Diazoxide.
Dofetilide The risk or severity of QTc prolongation can be increased when Quinethazone is combined with Dofetilide.
Ivabradine The risk or severity of Cardiac Arrhythmia can be increased when Quinethazone is combined with Ivabradine.
Lithium citrate Quinethazone may decrease the excretion rate of Lithium citrate which could result in a higher serum level.
Lithium carbonate Quinethazone may decrease the excretion rate of Lithium carbonate which could result in a higher serum level.
Lithium hydroxide Quinethazone may decrease the excretion rate of Lithium hydroxide which could result in a higher serum level.
Oxcarbazepine The risk or severity of hyponatremia can be increased when Quinethazone is combined with Oxcarbazepine.
Topiramate The risk or severity of hypokalemia can be increased when Quinethazone is combined with Topiramate.
Toremifene The risk or severity of hypercalcemia can be increased when Quinethazone is combined with Toremifene.
Methotrexate The protein binding of Methotrexate can be increased when combined with Quinethazone.
Sulpiride The risk or severity of orthostatic hypotension can be increased when Quinethazone is combined with Sulpiride.
Insulin human The risk or severity of hypoglycemia can be increased when Quinethazone is combined with Insulin human.
Insulin lispro The risk or severity of hypoglycemia can be increased when Quinethazone is combined with Insulin lispro.
Insulin glargine The risk or severity of hypoglycemia can be increased when Quinethazone is combined with Insulin glargine.
Insulin pork The risk or severity of hypoglycemia can be increased when Quinethazone is combined with Insulin pork.
Troglitazone The therapeutic efficacy of Troglitazone can be decreased when used in combination with Quinethazone.
Glimepiride The therapeutic efficacy of Glimepiride can be decreased when used in combination with Quinethazone.
Sulfisoxazole The therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Quinethazone.
Disopyramide The therapeutic efficacy of Disopyramide can be decreased when used in combination with Quinethazone.
Acarbose The therapeutic efficacy of Acarbose can be decreased when used in combination with Quinethazone.
Metformin The therapeutic efficacy of Metformin can be decreased when used in combination with Quinethazone.
Sulfadiazine The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Quinethazone.
Rosiglitazone The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Quinethazone.
Acetohexamide The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Quinethazone.
Quinine The therapeutic efficacy of Quinine can be decreased when used in combination with Quinethazone.
Miglitol The therapeutic efficacy of Miglitol can be decreased when used in combination with Quinethazone.
Chlorpropamide The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Quinethazone.
Nateglinide The therapeutic efficacy of Nateglinide can be decreased when used in combination with Quinethazone.
Pentamidine The therapeutic efficacy of Pentamidine can be decreased when used in combination with Quinethazone.
Mifepristone The therapeutic efficacy of Mifepristone can be decreased when used in combination with Quinethazone.
Tolazamide The therapeutic efficacy of Tolazamide can be decreased when used in combination with Quinethazone.
Repaglinide The therapeutic efficacy of Repaglinide can be decreased when used in combination with Quinethazone.
Phenformin The therapeutic efficacy of Phenformin can be decreased when used in combination with Quinethazone.
Sulfamethoxazole The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Quinethazone.
Glyburide The therapeutic efficacy of Glyburide can be decreased when used in combination with Quinethazone.
Glipizide The therapeutic efficacy of Glipizide can be decreased when used in combination with Quinethazone.
Gliclazide The therapeutic efficacy of Gliclazide can be decreased when used in combination with Quinethazone.
Tolbutamide The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Quinethazone.
Pioglitazone The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Quinethazone.
Bromocriptine The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Quinethazone.
Gliquidone The therapeutic efficacy of Gliquidone can be decreased when used in combination with Quinethazone.
Mitiglinide The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Quinethazone.
Sitagliptin The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Quinethazone.
Sunitinib The therapeutic efficacy of Sunitinib can be decreased when used in combination with Quinethazone.
Exenatide The therapeutic efficacy of Exenatide can be decreased when used in combination with Quinethazone.
Mecasermin The therapeutic efficacy of Mecasermin can be decreased when used in combination with Quinethazone.
Pramlintide The therapeutic efficacy of Pramlintide can be decreased when used in combination with Quinethazone.
Glisoxepide The therapeutic efficacy of Glisoxepide can be decreased when used in combination with Quinethazone.
Insulin aspart The risk or severity of hypoglycemia can be increased when Quinethazone is combined with Insulin aspart.
Insulin detemir The risk or severity of hypoglycemia can be increased when Quinethazone is combined with Insulin detemir.
Insulin glulisine The risk or severity of hypoglycemia can be increased when Quinethazone is combined with Insulin glulisine.
Glymidine The therapeutic efficacy of Glymidine can be decreased when used in combination with Quinethazone.
AICA ribonucleotide The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Quinethazone.
Buformin The therapeutic efficacy of Buformin can be decreased when used in combination with Quinethazone.
Vildagliptin The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Quinethazone.
Voglibose The therapeutic efficacy of Voglibose can be decreased when used in combination with Quinethazone.
NN344 The risk or severity of hypoglycemia can be increased when Quinethazone is combined with NN344.
AMG-222 The therapeutic efficacy of AMG-222 can be decreased when used in combination with Quinethazone.
Bisegliptin The therapeutic efficacy of Bisegliptin can be decreased when used in combination with Quinethazone.
Alogliptin The therapeutic efficacy of Alogliptin can be decreased when used in combination with Quinethazone.
Dapagliflozin The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Quinethazone.
Saxagliptin The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Quinethazone.
Liraglutide The therapeutic efficacy of Liraglutide can be decreased when used in combination with Quinethazone.
Gosogliptin The therapeutic efficacy of Gosogliptin can be decreased when used in combination with Quinethazone.
Linagliptin The therapeutic efficacy of Linagliptin can be decreased when used in combination with Quinethazone.
Canagliflozin The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Quinethazone.
Glibornuride The therapeutic efficacy of Glibornuride can be decreased when used in combination with Quinethazone.
Benfluorex The therapeutic efficacy of Benfluorex can be decreased when used in combination with Quinethazone.
Albiglutide The therapeutic efficacy of Albiglutide can be decreased when used in combination with Quinethazone.
Dulaglutide The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Quinethazone.
Lobeglitazone The therapeutic efficacy of Lobeglitazone can be decreased when used in combination with Quinethazone.
Netoglitazone The therapeutic efficacy of Netoglitazone can be decreased when used in combination with Quinethazone.
Rivoglitazone The therapeutic efficacy of Rivoglitazone can be decreased when used in combination with Quinethazone.
Ciglitazone The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Quinethazone.
Lixisenatide The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Quinethazone.
Insulin beef The risk or severity of hypoglycemia can be increased when Quinethazone is combined with Insulin beef.
Insulin degludec The risk or severity of hypoglycemia can be increased when Quinethazone is combined with Insulin degludec.
Insulin peglispro The risk or severity of hypoglycemia can be increased when Quinethazone is combined with Insulin peglispro.
Insulin tregopil The risk or severity of hypoglycemia can be increased when Quinethazone is combined with Insulin tregopil.
Ipragliflozin The therapeutic efficacy of Ipragliflozin can be decreased when used in combination with Quinethazone.
Dutogliptin The therapeutic efficacy of Dutogliptin can be decreased when used in combination with Quinethazone.
Allicin The therapeutic efficacy of Allicin can be decreased when used in combination with Quinethazone.
Tofogliflozin The therapeutic efficacy of Tofogliflozin can be decreased when used in combination with Quinethazone.
Ertugliflozin The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Quinethazone.
2,4-thiazolidinedione The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Quinethazone.
Teneligliptin The therapeutic efficacy of Teneligliptin can be decreased when used in combination with Quinethazone.
Omarigliptin The therapeutic efficacy of Omarigliptin can be decreased when used in combination with Quinethazone.
Carmegliptin The therapeutic efficacy of Carmegliptin can be decreased when used in combination with Quinethazone.
Gemigliptin The therapeutic efficacy of Gemigliptin can be decreased when used in combination with Quinethazone.
Anagliptin The therapeutic efficacy of Anagliptin can be decreased when used in combination with Quinethazone.
Evogliptin The therapeutic efficacy of Evogliptin can be decreased when used in combination with Quinethazone.

Target Protein

Solute carrier family 12 member 1 SLC12A1
Solute carrier family 12 member 2 SLC12A2
Solute carrier family 12 member 3 SLC12A3
Carbonic anhydrase 1 CA1
Carbonic anhydrase 2 CA2

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 0 • International brands: 3
International Brands
  • Aquamox
  • Hydromox
  • Idrokin

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul